Cargando…
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study
BACKGROUND AND AIMS: Multiple direct-acting antiviral (DAA) regimens are available to treat HCV genotype 1 infection. However, comparative effectiveness from randomized controlled trials of DAA regimens is unavailable. APPROACH AND RESULTS: We conducted a pragmatic randomized controlled trial (NCT02...
Autores principales: | Sulkowski, Mark S., Moon, Juhi S., Sherman, Kenneth E., Morelli, Giuseppe, Darling, Jama M., Muir, Andrew J., Khalili, Mandana, Fishbein, Dawn A., Hinestrosa, Federico, Shiffman, Mitchell L., Di Bisceglie, Adrian, Reddy, K. Rajender, Pearlman, Brian, Lok, Anna S., Fried, Michael W., Stewart, Paul W., Peter, Joy, Wadsworth, Summer, Kixmiller, Scott, Sloan, Anquenette, Vainorius, Monika, Horne, Patrick M., Michael, Larry, Dong, Meichen, Evon, Donna M., Segal, Jodi B., Nelson, David R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639765/ https://www.ncbi.nlm.nih.gov/pubmed/34255381 http://dx.doi.org/10.1002/hep.32053 |
Ejemplares similares
-
Experiences of an HCV Patient engagement group: a seven-year journey
por: Kixmiller, Scott, et al.
Publicado: (2021) -
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017) -
Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV‐TARGET Analysis
por: Radhakrishnan, Kavita, et al.
Publicado: (2019) -
Daclatasvir and sofosbuvir treatment of decompensated liver disease or post‐liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real‐world cohort
por: Kwo, Paul, et al.
Publicado: (2018) -
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study
por: Evon, Donna M., et al.
Publicado: (2018)